{
  "000705.SZ": {
    "city": "Shaoxing",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHZ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Zhejiang Zhenyuan Share Co., Ltd.",
    "market": "cn_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Z/ZHENYUAN SHARE C",
    "state": null,
    "summary": "Zhejiang Zhenyuan Share Co., Ltd. operates as a pharmaceutical company in China and internationally. It offers Chinese patent medicines, Chinese medicinal materials, Chinese herbal medicines, chemical preparations, chemical raw materials, biochemical drugs, anesthetics, psychotropic drugs, medical devices, chemical reagents, etc. The company offers its products under the Zhenyuan and Zhenyuantang brands. It serves pharmaceutical commerce and health service industries. The company was founded in 1752 and is based in Shaoxing, China.",
    "website": "http://www.zjzy.com",
    "zipcode": "312000"
  },
  "000908.SZ": {
    "city": "Shanghai",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHZ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Hunan Jingfeng Pharmaceutical Co.,Ltd.",
    "market": "cn_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HUNAN JINGFENG PHA",
    "state": null,
    "summary": "Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmology and API products, as well as engages in the research and development of anti-tumor, cancer, and cardiovascular drugs; and provides CMO services covering cell culture, microbial fermentation, biologics, and pre-filled platforms. The company was founded in 2003 and is headquartered in Shanghai, China.",
    "website": "http://www.jfzhiyao.com",
    "zipcode": "200120"
  },
  "000952.SZ": {
    "city": "Wuxue",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHZ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Hubei Guangji Pharmaceutical Co., Ltd.",
    "market": "cn_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HUBEI GUANGJI PHAR",
    "state": null,
    "summary": "Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, medicinal feed additives, fine chemicals, and preparations in China. The company also exports its products to approximately 30 countries and regions worldwide. Hubei Guangji Pharmaceutical Co., Ltd. was founded in 1969 and is based in Wuxue, China.",
    "website": "http://www.guangjipharm.com",
    "zipcode": "435400"
  },
  "002019.SZ": {
    "city": "Lin'an",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHZ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Yifan Pharmaceutical Co., Ltd.",
    "market": "cn_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "YIFAN PHARMACEUTIC",
    "state": null,
    "summary": "Yifan Pharmaceutical Co., Ltd. produces and sells drugs and medicines in China and internationally. It provides drugs across gynecology, pediatrics, orthopedics, and dermatology therapeutic areas; therapeutic infusion solutions; and pantothenic acid and Provitamin B5 products. The company also provides Chinese traditional medicines, women's health products, and blood tumor drugs. In addition, it offers APIs, including feed additives/animal health products, skin and hair care ingredients, functional food additives, and fine chemicals; and PBAT/PBS biodegradable resins and PVB films. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is based in Lin'an, China.",
    "website": "http://www.xinfupharm.com",
    "zipcode": "311300"
  },
  "002198.SZ": {
    "city": "Meizhou",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHZ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Guangdong Jiaying Pharmaceutical Co., Ltd",
    "market": "cn_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "GUANGDONG JIAYING",
    "state": null,
    "summary": "Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in Mainland China, Taiwan, Hong Kong and Macao, Southeast Asia, Europe, the United States, and internationally. The company provides medicines primarily for the treatment of throat, cold, orthopedics, rheumatism, gynecology, heat-clearing, and gastrointestinal diseases. It offers products in various dosage forms, such as powders, tablets, capsules, granules, and pills. The company sells its products through distribution agencies and sales outlets. Guangdong Jiaying Pharmaceutical Co., Ltd. is based in Meizhou, China.",
    "website": "http://www.gdjyzy.com.cn",
    "zipcode": null
  },
  "002399.SZ": {
    "city": "Shenzhen",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHZ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd.",
    "market": "cn_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SHENZHEN HEPALINK",
    "state": null,
    "summary": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through three segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), and CDMO. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, including pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; and trading of medical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.",
    "website": "http://www.hepalink.com",
    "zipcode": "518057"
  },
  "002422.SZ": {
    "city": "Chengdu",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHZ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Sichuan Kelun Pharmaceutical Co., Ltd.",
    "market": "cn_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SICHUAN KELUN PHAR",
    "state": null,
    "summary": "Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China and internationally. It offers infusion and non-infusion products, and new injection package. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.",
    "website": "http://www.kelun.com",
    "zipcode": "610071"
  },
  "003090.KS": {
    "city": "Hwaseong-si",
    "country": "South Korea",
    "currency": "KRW",
    "exchange": "KSC",
    "industry": "Drug Manufacturers - General",
    "long_name": "Daewoong Co., Ltd.",
    "market": "kr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Daewoong",
    "state": null,
    "summary": "Daewoong Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals. It also engages in the leasing of real estates. The company was formerly known as Daewoong Pharmaceutical Co., Ltd. and changed its name to Daewoong Co., Ltd. in 2002. Daewoong Co., Ltd. was founded in 1961 and is headquartered in Seongnam-si, South Korea.",
    "website": "http://www.daewoongholdings.com",
    "zipcode": null
  },
  "004720.KS": {
    "city": "Hwaseong-si",
    "country": "South Korea",
    "currency": "KRW",
    "exchange": "KSC",
    "industry": "Drug Manufacturers - General",
    "long_name": "PharmGen Science Inc.",
    "market": "kr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PharmGen Science",
    "state": null,
    "summary": "PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It offers prescription drugs, OTC drugs, health food, and cosmetics. It offers its products in the form of tablet, hard capsule, granule and ointment, syrups, and suspension forms. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1961 and is headquartered in Hwaseong, South Korea.",
    "website": "http://www.wooridulpharm.com",
    "zipcode": null
  },
  "008930.KS": {
    "city": "Seoul",
    "country": "South Korea",
    "currency": "KRW",
    "exchange": "KSC",
    "industry": "Drug Manufacturers - General",
    "long_name": "Hanmi Science Co., Ltd.",
    "market": "kr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Hanmi Science",
    "state": null,
    "summary": "Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is based in Seoul, South Korea.",
    "website": "http://www.hanmiscience.co.kr",
    "zipcode": null
  },
  "1093.HK": {
    "city": "Shijiazhuang",
    "country": "China",
    "currency": "HKD",
    "exchange": "HKG",
    "industry": "Drug Manufacturers - General",
    "long_name": "CSPC Pharmaceutical Group Limited",
    "market": "hk_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSPC PHARMA",
    "state": null,
    "summary": "CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke and memory and mental impairment; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Xuanning for hypertension; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; Enxi to treat adult idiopathic Parkinson's disease; Keaili for breast cancer; Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; and Encun to prevent atherosclerotic thrombosis events. It also offers Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; Gaoshunsong for arthritis, rheumatoid, and various pain; Debixin for various ulcer; and Qimaite for acute and chronic pains. In addition, the company provides antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and researches and develops various products with focus on the therapeutic areas of oncology, autoimmunity, psychiatry and neurology, digestion and metabolism, cardio-cerebrovascular system, and anti-infection. Further, it offers healthcare services and sells pharmaceutical equipment. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.",
    "website": "http://www.cspc.com.hk",
    "zipcode": "050035"
  },
  "118000.KS": {
    "city": "Hwaseong-si",
    "country": "South Korea",
    "currency": "KRW",
    "exchange": "KSC",
    "industry": "Drug Manufacturers - General",
    "long_name": "Wooridul Huebrain Limited",
    "market": "kr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "WOORIDUL HUEBRAIN",
    "state": null,
    "summary": "Wooridul Huebrain Limited engages in the medical, life and health, pharmaceutical, and storage businesses. It sells medical equipment and appliances, health equipment, medicines, and computer servers. Wooridul Huebrain Limited was formerly known as Wooridul Life Sciences Limited and changed its name to Wooridul Huebrain Limited in April 2014. Wooridul Huebrain Limited was founded in 2009 and is based in Seoul, South Korea.",
    "website": "http://www.wooridulls.co.kr",
    "zipcode": null
  },
  "1643.HK": {
    "city": "Chengde",
    "country": "China",
    "currency": "HKD",
    "exchange": "HKG",
    "industry": "Drug Manufacturers - General",
    "long_name": "Modern Chinese Medicine Group Co., Ltd.",
    "market": "hk_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MODERN CHI MED",
    "state": null,
    "summary": "Modern Chinese Medicine Group Co. Ltd. produces and sells Chinese medicines. The company was founded in 1986 and is based in Chengde, China.",
    "website": "http://www.cdysjdyy.com",
    "zipcode": "067000"
  },
  "1666.HK": {
    "city": "Beijing",
    "country": "China",
    "currency": "HKD",
    "exchange": "HKG",
    "industry": "Drug Manufacturers - General",
    "long_name": "Tong Ren Tang Technologies Co. Ltd.",
    "market": "hk_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TONG REN TANG",
    "state": null,
    "summary": "Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicines in Mainland China, Hong Kong, and internationally. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, foot care products, and healthcare products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in the technological development and sale of biological products, Chinese and Western medicines, and cosmetics; wholesale and retail sale of Chinese medicines and healthcare products; and internal and external surgery, medical examination, and hospital management activities. Further, it produces and processes biochemical products; extracts and processes plants; and produces food products. The company was founded in 1669 and is based in Beijing, the People's Republic of China.",
    "website": "http://www.tongrentangkj.com",
    "zipcode": "100079"
  },
  "1PK.F": {
    "city": "Northwich",
    "country": "United Kingdom",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Dechra Pharmaceuticals PLC",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "DECHRA PHARMACEUT. LS-,01",
    "state": null,
    "summary": "Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.",
    "website": "http://www.dechra.com",
    "zipcode": "CW9 7UA"
  },
  "2186.HK": {
    "city": "Yantai",
    "country": "China",
    "currency": "HKD",
    "exchange": "HKG",
    "industry": "Drug Manufacturers - General",
    "long_name": "Luye Pharma Group Ltd.",
    "market": "hk_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "LUYE PHARMA",
    "state": null,
    "summary": "Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and treatment for metastatic carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Tiandixin, a product used as an adjuvant therapy for malignant tumors, malignant hydrothorax and ascites, and respiratory infections; and Yitaida for acute promyelocytic leukemia and liver cancer. It also provides Rykindo, an injection for the treatment of acute and chronic schizophrenia; Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for the treatment of cancer pain; and Buprenorphine Transdermal Patch for the treatment of chronic pain. In addition, it offers Beixi, an acarbose capsule for diabetes; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; Beitangning, a pioglitazone hydrochloride capsule to control blood glucose; Nuosen for acute upper digestive tract hemorrhage; and Sailimai for the treatment of diarrhea. Further, it provides Xuezhikang, a lipid adjusting capsule; Maitongna for cerebral edema and swelling by trauma; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; Fengshiye for patients who have pains in bones, joints, and limbs; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; and glucosamine hydrochloride tablets for osteoarthritis. Additionally, it distributes and sells pharmaceutical drugs; and manufactures and sells of biopharmaceutical products. The company was founded in 1994 and is headquartered in Yantai, the People's Republic of China.",
    "website": "http://www.luye.cn",
    "zipcode": "264003"
  },
  "2FJ.F": {
    "city": "Capua",
    "country": "Italy",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pierrel S.p.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PIERREL S.P.A.",
    "state": "CE",
    "summary": "Pierrel S.p.A. provides contract manufacturing services to the life science, biopharma, and pharmaceutical industries worldwide. The company is involved in the development of various types of drugs, such as tube vials, bottles, ampoules, drops, sprays, syrups, gels, creams, ointments, and tablets; and production of active ingredients, including active substances and pharmaceutical formulations, as well as develops and manufactures dental anesthetics under the Orabloc brand name. It also engages in the development, registration, and licensing of new drugs and medical devices. Pierrel S.p.A. is based in Capua, Italy.",
    "website": "http://www.pierrelgroup.com",
    "zipcode": "81043"
  },
  "300006.SZ": {
    "city": "Chongqing",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHZ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Chongqing Lummy Pharmaceutical Co., Ltd.",
    "market": "cn_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CHONGQING LUMMY PH",
    "state": null,
    "summary": "Chongqing Lummy Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products in China. The company provides tumor, antibacterial, antiviral, and antifungal, as well as liver disease auxiliary, endocrinology system, and Chinese patent drugs; digestive system, immune system, blood system, cardiovascular system, and nervous system drugs; acid-base balance and nutritional products; and base large infusion products, American ginseng systems, and active pharmaceutical ingredients. Chongqing Lummy Pharmaceutical Co., Ltd. was founded in 1999 and is based in Chongqing, China.",
    "website": "http://www.cqlummy.com",
    "zipcode": "401336"
  },
  "300109.SZ": {
    "city": "Heping",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHZ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Boai NKY Medical Holdings Ltd.",
    "market": "cn_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NKY MEDICAL HOLDIN",
    "state": null,
    "summary": "Boai NKY Medical Holdings Ltd. develops, manufactures, and sells polyvinylpyrrolidone (PVP) series products worldwide. The company offers KoVidone and PolyKoVidone line of products representing Povidone, Crospovidone, and Copovidone pharmaceutical excipients; OraRez line of PVM/MA copolymer and derivatives representing functional polymers for bioadhesive/mucoadhesive applications; KoVidone-1 broad spectrum biocidal, antifungal, and antiviral agents; and pharmaceutical solvents and intermediates. It also offers polymers, vinyl and vinyl ether compounds, PolyViscol, KoVidone I, WhiVidone, and PVPP. Its products are used in pharma, industrial, oral care, cosmetics, and food and beverage. The company was formerly known as Boai NKY Pharmaceuticals Ltd. and changed its name to NKY medical holding Ltd. in March 2016. Boai NKY Medical Holdings Ltd. is based in Heping, the People's Republic of China.",
    "website": "http://www.boai-nky.com",
    "zipcode": "300200"
  },
  "300357.SZ": {
    "city": "Huzhou",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHZ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.",
    "market": "cn_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ZHEJIANG WOLWO BIO",
    "state": null,
    "summary": "Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, researches and develops, produces, and sells pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company is based in Huzhou, China.",
    "website": "http://www.wolwobiotech.com",
    "zipcode": null
  },
  "4102.TWO": {
    "city": "Taichung",
    "country": "Taiwan",
    "currency": "TWD",
    "exchange": "TWO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Yung Zip Chemical Ind. Co., Ltd.",
    "market": "tw_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "YUNG ZIP CHEMICAL IND CO LTD",
    "state": null,
    "summary": "Yung Zip Chemical Ind. Co., Ltd., a bulk drug manufacturing company, supplies active pharmaceutical ingredients (APIs), API intermediates, and specialty chemicals worldwide. It offers antihypertensive, antiviral, iron chelator, anti-inflammatory, analgesic, antipyretic, anti-fungal, schizophrenia, genital herpes outbreak, hypnotic, and sedative products. The company also offers excipients, such as sodium starch glycolate; and custom research and manufacturing services. The company was founded in 1978 and is based in Taichung, Taiwan.",
    "website": "http://www.yungzip.com",
    "zipcode": "43767"
  },
  "4151.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Kyowa Kirin Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "KYOWA KIRIN CO LTD",
    "state": null,
    "summary": "Kyowa Kirin Co., Ltd., a specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has strategic research alliance with Harvard University. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",
    "website": "http://www.kyowakirin.com",
    "zipcode": "100-0004"
  },
  "4503.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Astellas Pharma Inc.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTELLAS PHARMA",
    "state": null,
    "summary": "Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.",
    "website": "http://www.astellas.com",
    "zipcode": "103-8411"
  },
  "4519.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Chugai Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CHUGAI PHARMACEUTICAL CO",
    "state": null,
    "summary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.",
    "website": "http://www.chugai-pharm.co.jp",
    "zipcode": "103-8324"
  },
  "4528.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Ono Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ONO PHARMACEUTICAL CO",
    "state": null,
    "summary": "Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.",
    "website": "http://www.ono.co.jp",
    "zipcode": "541-8564"
  },
  "4536.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Santen Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SANTEN PHARMACEUTICAL CO",
    "state": null,
    "summary": "Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase 2b clinical trial; DE-128 in Europe, as well as is in Phase 2/3 clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase 3 clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase 2/3 clinical trial in Japan, as well as is in Phase 3 in Asia; and MD-16 for the treatment of cataract. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.",
    "website": "http://www.santen.com",
    "zipcode": "530-8552"
  },
  "4550.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Nissui Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NISSUI PHARMACEUTICAL CO",
    "state": null,
    "summary": "Nissui Pharmaceutical Co., Ltd. produces, sells, imports, and exports culture media and diagnostics for medical institutions, research organizations, and food industries in Japan and internationally. It offers in vitro diagnostics and medical devices; culture media for microbiological testing; products for antimicrobial susceptibility tests, microorganism identification, and immunological tests; and quality control serum, which is used for ensuring the accuracy of clinical diagnoses. In addition,, the company provides microbiological testing products for food poisoning detection; immunosorbent assays for the detection of allergies to food items, such as eggs, wheat, milk, shrimp, crabs, buckwheat, peanuts, etc.; and culture media and reagents for regenerative medicine. Further, it supplies testing agents and bulk products to diagnostic agent manufacturers; and CompactDry, a dry medium that is used for coliform counting for food manufacturers. The company was formerly known as Nissan Research Institute Co., Ltd. and changed its name to Nissui Pharmaceutical Co., Ltd. in 1962. Nissui Pharmaceutical Co., Ltd. was founded in 1935 and is headquartered in Tokyo, Japan.",
    "website": "http://www.nissui-pharm.co.jp",
    "zipcode": "110-8736"
  },
  "4552.T": {
    "city": "Ashiya",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "JCR Pharmaceuticals Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "JCR PHARMACEUTICAL CO",
    "state": null,
    "summary": "JCR Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, regenerative medicines, and drug substances primarily in Japan. The company offers GROWJECT, a recombinant human growth hormone for the treatment of short stature; Agalsidase Beta BS I.V. Infusion, a biosimilar for agalsidase beta for the treatment of Fabry disease, a type of lysosomal storage disorder; and TEMCELL HS Inj, a therapeutic product using mesenchymal stem cells for the treatment of acute graft-versus-host disease. It also develops biosimilar products for the treatment of renal anemia. The company was founded in 1975 and is headquartered in Ashiya, Japan.",
    "website": "http://www.jcrpharm.co.jp",
    "zipcode": "659-0021"
  },
  "4568.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Daiichi Sankyo Company, Limited",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "DAIICHI SANKYO COMPANY LIMITED",
    "state": null,
    "summary": "Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.",
    "website": "http://www.daiichisankyo.com",
    "zipcode": "103-8426"
  },
  "4578.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Otsuka Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OTSUKA HLDGS CO LTD",
    "state": null,
    "summary": "Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of central nervous system, oncology, cardiovascular system, gastroenterology, ophthalmology, diagnostics, and I.V. solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÃ Jelly, a conditioning food product; BODYMAINTÃ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; SOYJOY, a soy bar; OS-1, an oral rehydration solution; HINE E-GEL, a concentrated liquid diet; PROCESSLEAD, a chew and swallow managing food; REHADAYS, a beverage to support exercise and rehabilitation; Oronine H Ointment, a household antiseptic medicine; and vitamin tonics, herbal digestive drinks, and herbal crude drugs. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 2008 and is headquartered in Tokyo, Japan.",
    "website": "http://www.otsuka.com/en",
    "zipcode": "101-0048"
  },
  "4AB.DE": {
    "city": "North Chicago",
    "country": "United States",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "AbbVie Inc.",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ABBVIE INC.  DL-,01",
    "state": "IL",
    "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
    "website": "http://www.abbvie.com",
    "zipcode": "60064-6400"
  },
  "4AB.F": {
    "city": "North Chicago",
    "country": "United States",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "AbbVie Inc.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ABBVIE INC.  DL-,01",
    "state": "IL",
    "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
    "website": "http://www.abbvie.com",
    "zipcode": "60064-6400"
  },
  "600276.SS": {
    "city": "Lianyungang",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHH",
    "industry": "Drug Manufacturers - General",
    "long_name": "Jiangsu Hengrui Medicine Co., Ltd.",
    "market": "cn_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "JIANGSU HENGRUI MEDICAL CO LTD",
    "state": null,
    "summary": "Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.",
    "website": "http://www.hrs.com.cn",
    "zipcode": "222000"
  },
  "600385.SS": {
    "city": "Jinan",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHH",
    "industry": "Drug Manufacturers - General",
    "long_name": "Shandong Jintai Group Co., Ltd.",
    "market": "cn_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SHANDONG JINTAI GROUP",
    "state": null,
    "summary": "Shandong Jintai Group Co., Ltd. produces and distributes chemical reagent medicines in China. The company provides tablets, capsules, ointments, membranes, and others. It is also involved in the enterprise investment business, as well as in the provision of leasing services. The company is based in Jinan, China.",
    "website": "http://www.sdjintai.com.cn",
    "zipcode": "250100"
  },
  "600436.SS": {
    "city": "Zhangzhou",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHH",
    "industry": "Drug Manufacturers - General",
    "long_name": "Zhangzhou Pientzehuang Pharmaceutical., Ltd",
    "market": "cn_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ZHANGZHOU PIENTZEHUANG PHARMACE",
    "state": null,
    "summary": "Zhangzhou Pientzehuang Pharmaceutical., Ltd produces and sells Chinese medicines. The company's product categories include medicines and health products, healthy foods, cosmetics, daily chemicals, and medical apparatus and instruments. The company is based in Zhangzhou, China. Zhangzhou Pientzehuang Pharmaceutical., Ltd is a subsidiary of Zhangzhou Jiulongjiang Construction Co., Ltd.",
    "website": "http://www.zzpzh.com.cn",
    "zipcode": "363000"
  },
  "600572.SS": {
    "city": "Hangzhou",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHH",
    "industry": "Drug Manufacturers - General",
    "long_name": "Zhejiang CONBA Pharmaceutical Co.,Ltd.",
    "market": "cn_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ZHEJIANG CONBA PHARMACEUTICAL C",
    "state": null,
    "summary": "Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of traditional Chinese medicines and botanical products in China. It offers chemical medicines, Chinese patent medicines, eye health products, nutritional supplements, health supplies, healthy daily necessities and food products, and other personal care products. The company was formerly known as Lanxi Yunshan Pharmaceutical Factory and changed its name to Zhejiang CONBA Pharmaceutical Co.,Ltd. in October 1999. Zhejiang CONBA Pharmaceutical Co.,Ltd. was founded in 1969 and is headquartered in Hangzhou, China. Zhejiang CONBA Pharmaceutical Co.,Ltd. is a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd.",
    "website": "http://www.conbagroup.com",
    "zipcode": null
  },
  "600613.SS": {
    "city": "Shanghai",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHH",
    "industry": "Drug Manufacturers - General",
    "long_name": "Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd.",
    "market": "cn_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SHANGHAI SHENQI PHARM INVEST MA",
    "state": null,
    "summary": "Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceutical products primarily in China. It specializes in offering anti-tumor, cardio-cerebral vascular, and antifungal drugs, as well as cold and cough drugs under the miraculous brand, and medications for children under the Magic Doll name. The company also provides cantharidin sodium vitamin B6 injection under the Ai Yishu name for the treatment of cancer; Chinese medicines and chemical medicines; respiratory and digestive system medications; ginseng polysaccharide and cantharidin injections; and pediatric phlegm cough particles. In addition, it offers ethnic medicines; raw material medicines; drugs for rheumatic orthopedics, kidney, diarrhea, and gynecological menstruation; drugs under the Anshen Bunao name; sodium candida sulfate injections; Jie Yin Ling lotions; compound coral ginger solutions; and coral decoctions. Further, the company provides urea miconazole ointment complex products; cephalosporins; Yinqi Xinmai dripping pills; Yindan Xintai and Danxin Taidi pills; Metronidazole B6 tablets; Yuan Ye Zhike syrups; anti-particles; compound Shangfuning cream; and pediatric pharyngeal flat particles and clear toxic syrups. Additionally, it offers Keping, Paidui Jiangzhi, Zhizhike, Jinwugutong, Jingwu, and Tianma capsules; and Zhifan Zhike, Phenol yellow, Ganfu, and pediatric aminophenol alkylamine granules, as well as medications for injury, etc. The company also provides products in various other forms, such as sprays, films, tinctures, etc. It also operates under the magic, Guizhou, God, Speed Stop, and Qiang Lulu brand names. The company is based in Shanghai, China.",
    "website": "http://www.gzsq.com",
    "zipcode": "200003"
  },
  "600671.SS": {
    "city": "Lin'an City",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHH",
    "industry": "Drug Manufacturers - General",
    "long_name": "Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd",
    "market": "cn_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "HANGZHOU TIAN-MU-SHAN PHARMACEU",
    "state": null,
    "summary": "Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd engages in the Chinese medicine, Western medicine, biological medicine, raw material medicine, health food, Chinese herbal medicine, and pharmaceutical businesses in China. It offers pearl eyesight eye drops, river car made of capsules, Xiangdan injections, Fu Le granules, Eucommia granules, compound fresh bamboo leachate, heart worry films, Liuwei Dihuang oral liquids/pills, menthols, metal Dendrobium soft capsules, metal maple bucket particles, iron maple dust particles, pinellia lotions, Jinkui Shenqi pills, nourishing and concentrating syrups, compound wild chrysanthemum cold particles, and Lily solid gold oral solutions. The company was founded in 1958 and is based in Lin'an City, China.",
    "website": "http://www.hztmyy.com",
    "zipcode": "311300"
  },
  "600713.SS": {
    "city": "Nanjing",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHH",
    "industry": "Drug Manufacturers - General",
    "long_name": "NanJing Pharmaceutical Company Limited",
    "market": "cn_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NANJING PHARMACEUTICAL CO LTD",
    "state": null,
    "summary": "NanJing Pharmaceutical Company Limited engages pharmaceutical wholesale and retail businesses in China. It also operates approximately 510 pharmacy retail stores and an e-commerce platform. The company was founded in 1951 and is based in Nanjing, China.",
    "website": "http://www.njyy.com",
    "zipcode": null
  },
  "600771.SS": {
    "city": "Xi'an",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHH",
    "industry": "Drug Manufacturers - General",
    "long_name": "GuangYuYuan Chinese Herbal Medicine Co., Ltd.",
    "market": "cn_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "GUANGYUYUAN CHINESE HERBAL MEDI",
    "state": null,
    "summary": "GuangYuYuan Chinese Herbal Medicine Co., Ltd. manufactures and sells Chinese medicinal products. The company offers traditional Chinese medicines and health wines. It offers its products in the form of pills, capsules, and wine. The company was formerly known as Topsun Science And Technology Co Ltd. and changed its name to GuangYuYuan Chinese Herbal Medicine Co., Ltd. in July 2013. GuangYuYuan Chinese Herbal Medicine Co., Ltd. was founded in 1996 and is based in Xi'an, China.",
    "website": "http://www.guangyuyuan.com",
    "zipcode": "710065"
  },
  "600867.SS": {
    "city": "Tonghua",
    "country": "China",
    "currency": "CNY",
    "exchange": "SHH",
    "industry": "Drug Manufacturers - General",
    "long_name": "Tonghua Dongbao Pharmaceutical Co., Ltd.",
    "market": "cn_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "TONGHUA DONGBAO MEDICINES CO LT",
    "state": null,
    "summary": "Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products for the treatment of diabetes and cardiovascular-based diseases in China. The company operates through Pharmaceutical Industry and Building Materials Industry segments. It lead product portfolio includes insulin analogues, such as insulin glargine, Insulin aspart, insulin detemir, and insulin lispro; antidiabetic drug agonist products; oral hypoglycemic agents; and Zhen Nao Ning and Nao Xue Kang capsules, as well as Gan Shulin pens, blood glucose meters, and other medical devices. The company is also involved in developing Y-PEG of recombinant human interferon a 2b injection, which has been completed Phase III clinical stage to treat chronic hepatitis C (2,3 gene type) and chronic hepatitis B III; Y-PEG a recombinant human granulocyte colony-stimulating factor injection that is in Phase II clinical stage for the treatment of chemotherapy-induced neutropenia; Y-PEG injection of recombinant human growth hormone, which is in Phase II clinical stage to treat short stature and growth hormone deficiency; and Y-PEG of recombinant human interferon a 2a injection that is in Phase II clinical stage to treat chronic hepatitis B and hepatitis C. It offers building materials comprising plastic windows and sections; and other products. The company has a strategic alliance with Adocia. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is based in Tonghua, China.",
    "website": "http://www.thdb.com",
    "zipcode": "134123"
  },
  "900904.SS": {
    "city": "Shanghai",
    "country": "China",
    "currency": "USD",
    "exchange": "SHH",
    "industry": "Drug Manufacturers - General",
    "long_name": "Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd.",
    "market": "cn_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SHANGHAI SHENQI PHARM INVEST MA",
    "state": null,
    "summary": "Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceutical products primarily in China. It specializes in offering anti-tumor, cardio-cerebral vascular, and antifungal drugs, as well as cold and cough drugs under the miraculous brand, and medications for children under the Magic Doll name. The company also provides cantharidin sodium vitamin B6 injection under the Ai Yishu name for the treatment of cancer; Chinese medicines and chemical medicines; respiratory and digestive system medications; ginseng polysaccharide and cantharidin injections; and pediatric phlegm cough particles. In addition, it offers ethnic medicines; raw material medicines; drugs for rheumatic orthopedics, kidney, diarrhea, and gynecological menstruation; drugs under the Anshen Bunao name; sodium candida sulfate injections; Jie Yin Ling lotions; compound coral ginger solutions; and coral decoctions. Further, the company provides urea miconazole ointment complex products; cephalosporins; Yinqi Xinmai dripping pills; Yindan Xintai and Danxin Taidi pills; Metronidazole B6 tablets; Yuan Ye Zhike syrups; anti-particles; compound Shangfuning cream; and pediatric pharyngeal flat particles and clear toxic syrups. Additionally, it offers Keping, Paidui Jiangzhi, Zhizhike, Jinwugutong, Jingwu, and Tianma capsules; and Zhifan Zhike, Phenol yellow, Ganfu, and pediatric aminophenol alkylamine granules, as well as medications for injury, etc. The company also provides products in various other forms, such as sprays, films, tinctures, etc. It also operates under the magic, Guizhou, God, Speed Stop, and Qiang Lulu brand names. The company is based in Shanghai, China.",
    "website": "http://www.gzsq.com",
    "zipcode": "200003"
  },
  "9989.HK": {
    "city": "Shenzhen",
    "country": "China",
    "currency": "HKD",
    "exchange": "HKG",
    "industry": "Drug Manufacturers - General",
    "long_name": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd.",
    "market": "hk_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "HEPALINK",
    "state": null,
    "summary": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through three segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), and CDMO. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, including pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; and trading of medical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.",
    "website": "http://www.hepalink.com",
    "zipcode": "518057"
  },
  "ABBOTINDIA.NS": {
    "city": "Mumbai",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "Abbott India Limited",
    "market": "in_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ABBOTT INDIA LTD",
    "state": null,
    "summary": "Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolics, central nervous system, pain management, nutritional supplements, vitamins, insomnia, vaccines, consumer health, etc. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. Abbott India Limited was founded in 1944 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.",
    "website": "http://www.abbott.co.in",
    "zipcode": "400051"
  },
  "ABBV": {
    "city": "North Chicago",
    "country": "United States",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - General",
    "long_name": "AbbVie Inc.",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "AbbVie Inc.",
    "state": "IL",
    "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
    "website": "http://www.abbvie.com",
    "zipcode": "60064-6400"
  },
  "ABBV.BA": {
    "city": "North Chicago",
    "country": "United States",
    "currency": "ARS",
    "exchange": "BUE",
    "industry": "Drug Manufacturers - General",
    "long_name": "AbbVie Inc.",
    "market": "ar_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "ABBVIE INC",
    "state": "IL",
    "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
    "website": "http://www.abbvie.com",
    "zipcode": "60064-6400"
  },
  "ABBV.MX": {
    "city": "North Chicago",
    "country": "United States",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "AbbVie Inc.",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ABBVIE INC",
    "state": "IL",
    "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
    "website": "http://www.abbvie.com",
    "zipcode": "60064-6400"
  },
  "ABBV.VI": {
    "city": "North Chicago",
    "country": "United States",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "AbbVie Inc.",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ABBVIE INC",
    "state": "IL",
    "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
    "website": "http://www.abbvie.com",
    "zipcode": "60064-6400"
  },
  "ABBV34.SA": {
    "city": "North Chicago",
    "country": "United States",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "AbbVie Inc.",
    "market": "br_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ABBVIE      DRN",
    "state": "IL",
    "summary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.",
    "website": "http://www.abbvie.com",
    "zipcode": "60064-6400"
  },
  "ABLI.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Abliva AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Abliva AB",
    "state": null,
    "summary": "Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
    "website": "http://abliva.com",
    "zipcode": "223 81"
  },
  "ALECR.PA": {
    "city": "Vienne",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Drug Manufacturers - General",
    "long_name": "Eurofins-Cerep SA",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EUROFINS CEREP",
    "state": null,
    "summary": "Eurofins Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. The company's research services include compound management, high-throughput screening, in vitro safety profiling, lead optimization (or SAR) profiling, in vitro ADME profiling, and in vivo PK. It also offers assay design and development services. The company was formerly known as Cerep SA and changed its name to Eurofins Cerep SA in June 2014. Eurofins Cerep SA was founded in 1989 and is based in Vienne, France.",
    "website": "http://www.eurofins.fr/cerep",
    "zipcode": "86600"
  },
  "ALPMF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Astellas Pharma Inc.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTELLAS PHARMA",
    "state": null,
    "summary": "Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.",
    "website": "http://www.astellas.com",
    "zipcode": "103-8411"
  },
  "ALPMY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Astellas Pharma Inc.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTELLAS PHARMA",
    "state": null,
    "summary": "Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.",
    "website": "http://www.astellas.com",
    "zipcode": "103-8411"
  },
  "AMG.DE": {
    "city": "Thousand Oaks",
    "country": "United States",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "Amgen Inc.",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "AMGEN INC.  DL-,0001",
    "state": "CA",
    "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
    "website": "http://www.amgen.com",
    "zipcode": "91320-1799"
  },
  "AMG.F": {
    "city": "Thousand Oaks",
    "country": "United States",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Amgen Inc.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "AMGEN INC.  DL-,0001",
    "state": "CA",
    "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
    "website": "http://www.amgen.com",
    "zipcode": "91320-1799"
  },
  "AMGN": {
    "city": "Thousand Oaks",
    "country": "United States",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Amgen Inc.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Amgen Inc.",
    "state": "CA",
    "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
    "website": "http://www.amgen.com",
    "zipcode": "91320-1799"
  },
  "AMGN.MX": {
    "city": "Thousand Oaks",
    "country": "United States",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Amgen Inc.",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "AMGEN INC",
    "state": "CA",
    "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
    "website": "http://www.amgen.com",
    "zipcode": "91320-1799"
  },
  "AMGN.VI": {
    "city": "Thousand Oaks",
    "country": "United States",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Amgen Inc.",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "AMGEN INC",
    "state": "CA",
    "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
    "website": "http://www.amgen.com",
    "zipcode": "91320-1799"
  },
  "AMGN34.SA": {
    "city": "Thousand Oaks",
    "country": "United States",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Amgen Inc.",
    "market": "br_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "AMGEN       DRN",
    "state": "CA",
    "summary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",
    "website": "http://www.amgen.com",
    "zipcode": "91320-1799"
  },
  "AZN": {
    "city": "Cambridge",
    "country": "United Kingdom",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - General",
    "long_name": "AstraZeneca PLC",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Astrazeneca PLC",
    "state": null,
    "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; and Alchemab to enhance prostate cancer research. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
    "website": "http://www.astrazeneca.com",
    "zipcode": "CB2 0AA"
  },
  "AZN.BA": {
    "city": "Cambridge",
    "country": "United Kingdom",
    "currency": "ARS",
    "exchange": "BUE",
    "industry": "Drug Manufacturers - General",
    "long_name": "AstraZeneca PLC",
    "market": "ar_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ASTRAZENECA",
    "state": null,
    "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
    "website": "http://www.astrazeneca.com",
    "zipcode": "CB2 0AA"
  },
  "AZN.L": {
    "city": "Cambridge",
    "country": "United Kingdom",
    "currency": "GBp",
    "exchange": "LSE",
    "industry": "Drug Manufacturers - General",
    "long_name": "AstraZeneca PLC",
    "market": "gb_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "ASTRAZENECA PLC ORD SHS $0.25",
    "state": null,
    "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; and Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
    "website": "http://www.astrazeneca.com",
    "zipcode": "CB2 0AA"
  },
  "AZN.ST": {
    "city": "Cambridge",
    "country": "United Kingdom",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - General",
    "long_name": "AstraZeneca PLC",
    "market": "se_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "AstraZeneca PLC",
    "state": null,
    "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
    "website": "http://www.astrazeneca.com",
    "zipcode": "CB2 0AA"
  },
  "AZNCF": {
    "city": "Cambridge",
    "country": "United Kingdom",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "AstraZeneca PLC",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTRAZENECA",
    "state": null,
    "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
    "website": "http://www.astrazeneca.com",
    "zipcode": "CB2 0AA"
  },
  "AZNN.MX": {
    "city": "Cambridge",
    "country": "United Kingdom",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "AstraZeneca PLC",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTRAZENECA",
    "state": null,
    "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
    "website": "http://www.astrazeneca.com",
    "zipcode": "CB2 0AA"
  },
  "BAY.MI": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "MIL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "it_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYA.F": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER ADR /1/4",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYN.DE": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER AG NA O.N.",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYN.F": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER AG NA O.N.",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYN.VI": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER AG",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYRY": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER AG",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BAYZF": {
    "city": "Leverkusen",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bayer Aktiengesellschaft",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BAYER AG",
    "state": null,
    "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum JÃ¼lich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.",
    "website": "http://www.bayer.com",
    "zipcode": "51368"
  },
  "BIIB": {
    "city": "Cambridge",
    "country": "United States",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Biogen Inc.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Biogen Inc.",
    "state": "MA",
    "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
    "website": "http://www.biogen.com",
    "zipcode": "02142"
  },
  "BIIB.BA": {
    "city": "Cambridge",
    "country": "United States",
    "currency": "ARS",
    "exchange": "BUE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Biogen Inc.",
    "market": "ar_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BIOGEN INC",
    "state": "MA",
    "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
    "website": "http://www.biogen.com",
    "zipcode": "02142"
  },
  "BIIB.MX": {
    "city": "Cambridge",
    "country": "United States",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Biogen Inc.",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BIOGEN INC",
    "state": "MA",
    "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
    "website": "http://www.biogen.com",
    "zipcode": "02142"
  },
  "BIIB.VI": {
    "city": "Cambridge",
    "country": "United States",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Biogen Inc.",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BIOGEN INC",
    "state": "MA",
    "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
    "website": "http://www.biogen.com",
    "zipcode": "02142"
  },
  "BIIB34.SA": {
    "city": "Cambridge",
    "country": "United States",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Biogen Inc.",
    "market": "br_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BIOGEN      DRN",
    "state": "MA",
    "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
    "website": "http://www.biogen.com",
    "zipcode": "02142"
  },
  "BMY": {
    "city": "New York",
    "country": "United States",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bristol-Myers Squibb Company",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Bristol-Myers Squibb Company",
    "state": "NY",
    "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
    "website": "http://www.bms.com",
    "zipcode": "10016"
  },
  "BMY.MX": {
    "city": "New York",
    "country": "United States",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bristol-Myers Squibb Company",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BRISTOL-MYERS SQUIBB CO",
    "state": "NY",
    "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
    "website": "http://www.bms.com",
    "zipcode": "10016"
  },
  "BMYB34.SA": {
    "city": "New York",
    "country": "United States",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bristol-Myers Squibb Company",
    "market": "br_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BRISTOLMYERSDRN",
    "state": "NY",
    "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
    "website": "http://www.bms.com",
    "zipcode": "10016"
  },
  "BMYS.VI": {
    "city": "New York",
    "country": "United States",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bristol-Myers Squibb Company",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BRISTOL-MYERS SQUIBB CO",
    "state": "NY",
    "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
    "website": "http://www.bms.com",
    "zipcode": "10016"
  },
  "BRM.DE": {
    "city": "New York",
    "country": "United States",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bristol-Myers Squibb Company",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BRISTOL-MYERS SQUIBBDL-10",
    "state": "NY",
    "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
    "website": "http://www.bms.com",
    "zipcode": "10016"
  },
  "BRM.F": {
    "city": "New York",
    "country": "United States",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Bristol-Myers Squibb Company",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BRISTOL-MYERS SQUIBBDL-10",
    "state": "NY",
    "summary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.",
    "website": "http://www.bms.com",
    "zipcode": "10016"
  },
  "C43.F": {
    "city": "Dublin",
    "country": "Ireland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Cosmo Pharmaceuticals N.V.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "COSMO PHARMACEUT.  EO-,26",
    "state": null,
    "summary": "Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. The company offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; Aemcolo, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth, as well as Rifamycin for irritable bowel syndrome with diarrhoea; and Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early stage cancers, or other gastrointestinal mucosal lesions. It also provides ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for the induction and maintenance of procedural sedation; Qolotag, a medical device that enhances the visualisation of lesions during sigmoidoscopies; Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.",
    "website": "http://www.cosmopharma.com",
    "zipcode": "2"
  },
  "CHGCF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Chugai Pharmaceutical Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CHUGAI PHARMACEUTICAL CO",
    "state": null,
    "summary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.",
    "website": "http://www.chugai-pharm.co.jp",
    "zipcode": "103-8324"
  },
  "CHGCY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Chugai Pharmaceutical Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CHUGAI PHARMACEUTICAL CO",
    "state": null,
    "summary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.",
    "website": "http://www.chugai-pharm.co.jp",
    "zipcode": "103-8324"
  },
  "CIPLA.NS": {
    "city": "Mumbai",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "Cipla Limited",
    "market": "in_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CIPLA LTD",
    "state": null,
    "summary": "Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other dosage forms consists of injectables and biosimilars. Cipla Limited has collaboration with CSIR-Indian Institute of Chemical Technology for the development of medication for the treatment of COVID-19; and partnership with Karwa Ltd. for the commercialization of antibody detection kits for COVID-19, as well as the Premier Medical Corporation Private Limited for the commercialization of the rapid antigen test kits for COVID-19. The company was founded in 1935 and is headquartered in Mumbai, India.",
    "website": "http://www.cipla.com",
    "zipcode": "400013"
  },
  "COPN.SW": {
    "city": "Dublin",
    "country": "Ireland",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Cosmo Pharmaceuticals N.V.",
    "market": "ch_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "COSMO PHARM N",
    "state": null,
    "summary": "Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. The company offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; Aemcolo, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth, as well as Rifamycin for irritable bowel syndrome with diarrhoea; and Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early stage cancers, or other gastrointestinal mucosal lesions. It also provides ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for the induction and maintenance of procedural sedation; Qolotag, a medical device that enhances the visualisation of lesions during sigmoidoscopies; Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.",
    "website": "http://www.cosmopharma.com",
    "zipcode": "2"
  },
  "CUP.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Chugai Pharmaceutical Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CHUGAI PHARMACEUT'L",
    "state": null,
    "summary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.",
    "website": "http://www.chugai-pharm.co.jp",
    "zipcode": "103-8324"
  },
  "CVG.F": {
    "city": "Shijiazhuang",
    "country": "China",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "CSPC Pharmaceutical Group Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSPC PHARMACEUT.GR.",
    "state": null,
    "summary": "CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke and memory and mental impairment; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Xuanning for hypertension; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; Enxi to treat adult idiopathic Parkinson's disease; Keaili for breast cancer; Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; and Encun to prevent atherosclerotic thrombosis events. It also offers Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; Gaoshunsong for arthritis, rheumatoid, and various pain; Debixin for various ulcer; and Qimaite for acute and chronic pains. In addition, the company provides antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and researches and develops various products with focus on the therapeutic areas of oncology, autoimmunity, psychiatry and neurology, digestion and metabolism, cardio-cerebrovascular system, and anti-infection. Further, it offers healthcare services and sells pharmaceutical equipment. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.",
    "website": "http://www.cspc.com.hk",
    "zipcode": "050035"
  },
  "D4S.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Daiichi Sankyo Company, Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "DAIICHI SANKYO CO. LTD",
    "state": null,
    "summary": "Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.",
    "website": "http://www.daiichisankyo.com",
    "zipcode": "103-8426"
  },
  "DJNJ3.BA": {
    "city": "New Brunswick",
    "country": "United States",
    "currency": "ARS",
    "exchange": "BUE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Johnson & Johnson",
    "market": "ar_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "JOHNSON & JOHNSON",
    "state": "NJ",
    "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
    "website": "http://www.jnj.com",
    "zipcode": "08933"
  },
  "DPH.L": {
    "city": "Northwich",
    "country": "United Kingdom",
    "currency": "GBp",
    "exchange": "LSE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Dechra Pharmaceuticals PLC",
    "market": "gb_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "DECHRA PHARMACEUTICALS PLC ORD ",
    "state": null,
    "summary": "Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.",
    "website": "http://www.dechra.com",
    "zipcode": "CW9 7UA"
  },
  "DSKYF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Daiichi Sankyo Company, Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "DAIICHI SANKYO COMPANY LIMITED",
    "state": null,
    "summary": "Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.",
    "website": "http://www.daiichisankyo.com",
    "zipcode": "103-8426"
  },
  "DSNKY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Daiichi Sankyo Company, Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "DAIICHI SANKYO COMPANY LIMITED",
    "state": null,
    "summary": "Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.",
    "website": "http://www.daiichisankyo.com",
    "zipcode": "103-8426"
  },
  "ECILC.IS": {
    "city": "Istanbul",
    "country": "Turkey",
    "currency": "TRY",
    "exchange": "IST",
    "industry": "Drug Manufacturers - General",
    "long_name": "EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.",
    "market": "tr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ECZACIBASI ILAC",
    "state": null,
    "summary": "EIS Eczacibasi IlaÃ§, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S., together with subsidiaries, engages in health and real estate development businesses primarily in Turkey. The company's Health segment produces and sells human health and veterinary medicines. Its Real Estate Development segment develops real estate properties. The company was founded in 1951 and is based in Istanbul, Turkey. EIS Eczacibasi IlaÃ§, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a subsidiary of Eczacibasi Holding A.S.",
    "website": "http://www.eczacibasi.com.tr/en/eczacibasi-gruop/companies/other-products-and-services",
    "zipcode": "34394"
  },
  "G0FB.F": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS SP.ADR B EO-,10 1",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "GIFLF": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS SA",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "GIKLY": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS SA",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "GILD": {
    "city": "Foster City",
    "country": "United States",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Gilead Sciences, Inc.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Gilead Sciences, Inc.",
    "state": "CA",
    "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
    "website": "http://www.gilead.com",
    "zipcode": "94404"
  },
  "GILD.BA": {
    "city": "Foster City",
    "country": "United States",
    "currency": "ARS",
    "exchange": "BUE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Gilead Sciences, Inc.",
    "market": "ar_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GILEAD SCIENCES",
    "state": "CA",
    "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
    "website": "http://www.gilead.com",
    "zipcode": "94404"
  },
  "GILD.MI": {
    "city": "Foster City",
    "country": "United States",
    "currency": "EUR",
    "exchange": "MIL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Gilead Sciences, Inc.",
    "market": "it_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GILEAD SCIENCES",
    "state": "CA",
    "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
    "website": "http://www.gilead.com",
    "zipcode": "94404"
  },
  "GILD.MX": {
    "city": "Foster City",
    "country": "United States",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Gilead Sciences, Inc.",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GILEAD SCIENCES INC",
    "state": "CA",
    "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
    "website": "http://www.gilead.com",
    "zipcode": "94404"
  },
  "GILD.SN": {
    "city": "Foster City",
    "country": "United States",
    "currency": "USD",
    "exchange": "SGO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Gilead Sciences, Inc.",
    "market": "cl_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GILEAD SCIENCES",
    "state": "CA",
    "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
    "website": "http://www.gilead.com",
    "zipcode": "94404"
  },
  "GILD.VI": {
    "city": "Foster City",
    "country": "United States",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Gilead Sciences, Inc.",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GILEAD SCIENCES INC",
    "state": "CA",
    "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
    "website": "http://www.gilead.com",
    "zipcode": "94404"
  },
  "GILD34.SA": {
    "city": "Foster City",
    "country": "United States",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Gilead Sciences, Inc.",
    "market": "br_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GILEAD      DRN",
    "state": "CA",
    "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
    "website": "http://www.gilead.com",
    "zipcode": "94404"
  },
  "GIS.DE": {
    "city": "Foster City",
    "country": "United States",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "Gilead Sciences, Inc.",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GILEAD SCIENCES  DL-,001",
    "state": "CA",
    "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
    "website": "http://www.gilead.com",
    "zipcode": "94404"
  },
  "GIS.F": {
    "city": "Foster City",
    "country": "United States",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Gilead Sciences, Inc.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GILEAD SCIENCES  DL-,001",
    "state": "CA",
    "summary": "Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.",
    "website": "http://www.gilead.com",
    "zipcode": "94404"
  },
  "GLAND.NS": {
    "city": "Hyderabad",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "Gland Pharma Limited",
    "market": "in_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Gland Pharma Limited",
    "state": null,
    "summary": "Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neuro/Cns, respiratory, blood related, ophthalmological and otological, pain/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business to business in the United States, Europe, Canada, Australia, India, and the rest of the world. The company was founded in 1978 and is based in Hyderabad, India. As of October 3, 2017, Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.",
    "website": "http://www.glandpharma.com",
    "zipcode": "500043"
  },
  "GLAXF": {
    "city": "Brentford",
    "country": "United Kingdom",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "GlaxoSmithKline plc",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GLAXOSMITHKLINE",
    "state": null,
    "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
    "website": "http://www.gsk.com",
    "zipcode": "TW8 9GS"
  },
  "GLAXO.NS": {
    "city": "Mumbai",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "GlaxoSmithKline Pharmaceuticals Limited",
    "market": "in_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "GLAXO SMITHKLINE P",
    "state": null,
    "summary": "GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for asthma, infectious diseases, mental health, and digestive conditions, as well as anti-infective, gastrointestinal, nutrition, dermatology, immuno-inflammation, and respiratory diseases. It also provides vaccines for the treatment of cancer, as well as prevention of hepatitis A, hepatitis B, invasive disease caused by influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, invasive pneumococcal, and others; and consumer healthcare products. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was founded in 1924 and is headquartered in Mumbai, India.",
    "website": "http://www.india-pharma.gsk.com",
    "zipcode": "400030"
  },
  "GRF.MC": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "es_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS S.A.",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "GRF.VI": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS SA",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "GRFS": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Grifols, S.A.",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "GS7.DE": {
    "city": "Brentford",
    "country": "United Kingdom",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "GlaxoSmithKline plc",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GLAXOSMITHKLINE  LS-,25",
    "state": null,
    "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
    "website": "http://www.gsk.com",
    "zipcode": "TW8 9GS"
  },
  "GS7.F": {
    "city": "Brentford",
    "country": "United Kingdom",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "GlaxoSmithKline plc",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GLAXOSMITHKLINE  LS-,25",
    "state": null,
    "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
    "website": "http://www.gsk.com",
    "zipcode": "TW8 9GS"
  },
  "GS7A.F": {
    "city": "Brentford",
    "country": "United Kingdom",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "GlaxoSmithKline plc",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GLAXOSMITHKLINE SP. ADR/2",
    "state": null,
    "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
    "website": "http://www.gsk.com",
    "zipcode": "TW8 9GS"
  },
  "GSK": {
    "city": "Brentford",
    "country": "United Kingdom",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - General",
    "long_name": "GlaxoSmithKline plc",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GlaxoSmithKline PLC",
    "state": null,
    "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
    "website": "http://www.gsk.com",
    "zipcode": "TW8 9GS"
  },
  "GSK.L": {
    "city": "Brentford",
    "country": "United Kingdom",
    "currency": "GBp",
    "exchange": "LSE",
    "industry": "Drug Manufacturers - General",
    "long_name": "GlaxoSmithKline plc",
    "market": "gb_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "GLAXOSMITHKLINE PLC ORD 25P",
    "state": null,
    "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
    "website": "http://www.gsk.com",
    "zipcode": "TW8 9GS"
  },
  "GSKN.MX": {
    "city": "Brentford",
    "country": "United Kingdom",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "GlaxoSmithKline plc",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GLAXOSMITHKLINE",
    "state": null,
    "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
    "website": "http://www.gsk.com",
    "zipcode": "TW8 9GS"
  },
  "GW2A.F": {
    "city": "Cambridge",
    "country": "United Kingdom",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "GW Pharmaceuticals plc",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "GW PHARMACEUT.SPON.ADR/12",
    "state": null,
    "summary": "GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.",
    "website": "http://www.gwpharm.com",
    "zipcode": "CB24 9BZ"
  },
  "GWPH": {
    "city": "Cambridge",
    "country": "United Kingdom",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - General",
    "long_name": "GW Pharmaceuticals plc",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "GW Pharmaceuticals Plc",
    "state": null,
    "summary": "GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.",
    "website": "http://www.gwpharm.com",
    "zipcode": "CB24 9BZ"
  },
  "H02.SI": {
    "city": "Singapore",
    "country": "Singapore",
    "currency": "SGD",
    "exchange": "SES",
    "industry": "Drug Manufacturers - General",
    "long_name": "Haw Par Corporation Limited",
    "market": "sg_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Haw Par",
    "state": null,
    "summary": "Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally. The company operates through three segments: Healthcare, Investments, and Others. The Healthcare segment principally manufactures and distributes topical analgesic products. This segment offers ointments, plasters, back pain and ultra thin patches, muscle and joint rubs, neck and shoulder rubs, neck and shoulder rub boosts, mosquito repellent sprays and aerosols, mosquito repellent patches, fever patches, liniments/oils, lotions, muscle gels and sprays, and inhalers under the Tiger Balm brand; and medicated oils and refreshers under the Kwan Loong brand. The Investments segment invests primarily in quoted securities. The Others segment owns and leases various investment properties that have lettable area of 45,398 square meters of commercial and industrial space in Singapore and Malaysia. This segment also provides family and tourist oriented leisure alternatives principally in the form of oceanariums. Haw Par Corporation Limited also develops properties; leases office space; licenses Kwan Loong trademark; and offers management support services. The company was formerly known as Haw Par Brothers International Limited and changed its name to Haw Par Corporation Limited in 1997. Haw Par Corporation Limited was incorporated in 1969 and is based in Singapore.",
    "website": "http://www.hawpar.com",
    "zipcode": "149598"
  },
  "H1ZN34.SA": {
    "city": "Dublin",
    "country": "Ireland",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Horizon Therapeutics Public Limited Company",
    "market": "br_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "HORIZON THERDRN",
    "state": null,
    "summary": "Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chronic granulomatous disease and severe malignant osteopetrosis; RAYOS for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, primary systemic amyloidosis, asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, and other conditions; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and AS to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.",
    "website": "http://www.horizontherapeutics.com",
    "zipcode": "4"
  },
  "HAWPF": {
    "city": "Singapore",
    "country": "Singapore",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Haw Par Corporation Limited",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "HAW PAR CORP LTD",
    "state": null,
    "summary": "Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally. The company operates through three segments: Healthcare, Investments, and Others. The Healthcare segment principally manufactures and distributes topical analgesic products. This segment offers ointments, plasters, back pain and ultra thin patches, muscle and joint rubs, neck and shoulder rubs, neck and shoulder rub boosts, mosquito repellent sprays and aerosols, mosquito repellent patches, fever patches, liniments/oils, lotions, muscle gels and sprays, and inhalers under the Tiger Balm brand; and medicated oils and refreshers under the Kwan Loong brand. The Investments segment invests primarily in quoted securities. The Others segment owns and leases various investment properties that have lettable area of 45,398 square meters of commercial and industrial space in Singapore and Malaysia. This segment also provides family and tourist oriented leisure alternatives principally in the form of oceanariums. Haw Par Corporation Limited also develops properties; leases office space; licenses Kwan Loong trademark; and offers management support services. The company was formerly known as Haw Par Brothers International Limited and changed its name to Haw Par Corporation Limited in 1997. Haw Par Corporation Limited was incorporated in 1969 and is based in Singapore.",
    "website": "http://www.hawpar.com",
    "zipcode": "149598"
  },
  "HG6.F": {
    "city": "Salisbury South",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Mayne Pharma Group Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MAYNE PHARMA GROUP LTD.",
    "state": "SA",
    "summary": "Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. The company operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. It also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.",
    "website": "http://www.maynepharma.com",
    "zipcode": "5106"
  },
  "HPR.F": {
    "city": "Dublin",
    "country": "Ireland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Horizon Therapeutics Public Limited Company",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "HORIZON THERAP.PLC DL-,01",
    "state": null,
    "summary": "Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chronic granulomatous disease and severe malignant osteopetrosis; RAYOS for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, primary systemic amyloidosis, asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, and other conditions; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and AS to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.",
    "website": "http://www.horizontherapeutics.com",
    "zipcode": "4"
  },
  "HZNP": {
    "city": "Dublin",
    "country": "Ireland",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Horizon Therapeutics Public Limited Company",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Horizon Therapeutics Public Lim",
    "state": null,
    "summary": "Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chronic granulomatous disease and severe malignant osteopetrosis; RAYOS for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, primary systemic amyloidosis, asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, and other conditions; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and AS to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.",
    "website": "http://www.horizontherapeutics.com",
    "zipcode": "4"
  },
  "IDP.DE": {
    "city": "Cambridge",
    "country": "United States",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "Biogen Inc.",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BIOGEN INC. DL -,0005",
    "state": "MA",
    "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
    "website": "http://www.biogen.com",
    "zipcode": "02142"
  },
  "IDP.F": {
    "city": "Cambridge",
    "country": "United States",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Biogen Inc.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "BIOGEN INC. DL -,0005",
    "state": "MA",
    "summary": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
    "website": "http://www.biogen.com",
    "zipcode": "02142"
  },
  "IHAI": {
    "city": "Alpharetta",
    "country": "United States",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Innovative Holdings Alliance, Inc.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "INNOVATIVE HOLDINGS ALLIANCE IN",
    "state": "GA",
    "summary": "Innovative Holdings Alliance, Inc., a medical technology holding company, offers personal care products in North America. The company offers arthritis cream product, a topical ointment that is used for site specific applications to provide temporary relief of pain and inflammation associated with arthritis and other musculoskeletal conditions. The company was formerly known as Innovative Health Sciences, Inc. and changed its name to Innovative Holdings Alliance, Inc. in May 2011. Innovative Holdings Alliance, Inc. was founded in 1996 and is based in Alpharetta, Georgia.",
    "website": null,
    "zipcode": "30039"
  },
  "JNJ": {
    "city": "New Brunswick",
    "country": "United States",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Johnson & Johnson",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "Johnson & Johnson",
    "state": "NJ",
    "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
    "website": "http://www.jnj.com",
    "zipcode": "08933"
  },
  "JNJ.BA": {
    "city": "New Brunswick",
    "country": "United States",
    "currency": "ARS",
    "exchange": "BUE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Johnson & Johnson",
    "market": "ar_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "JOHNSON & JOHNSON",
    "state": "NJ",
    "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
    "website": "http://www.jnj.com",
    "zipcode": "08933"
  },
  "JNJ.DE": {
    "city": "New Brunswick",
    "country": "United States",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "Johnson & Johnson",
    "market": "de_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "JOHNSON + JOHNSON  DL 1",
    "state": "NJ",
    "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
    "website": "http://www.jnj.com",
    "zipcode": "08933"
  },
  "JNJ.F": {
    "city": "New Brunswick",
    "country": "United States",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Johnson & Johnson",
    "market": "dr_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "JOHNSON + JOHNSON  DL 1",
    "state": "NJ",
    "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
    "website": "http://www.jnj.com",
    "zipcode": "08933"
  },
  "JNJ.MX": {
    "city": "New Brunswick",
    "country": "United States",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Johnson & Johnson",
    "market": "mx_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "JOHNSON & JOHNSON",
    "state": "NJ",
    "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
    "website": "http://www.jnj.com",
    "zipcode": "08933"
  },
  "JNJ.SN": {
    "city": "New Brunswick",
    "country": "United States",
    "currency": "USD",
    "exchange": "SGO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Johnson & Johnson",
    "market": "cl_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "JOHNSON & JOHNSON",
    "state": "NJ",
    "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
    "website": "http://www.jnj.com",
    "zipcode": "08933"
  },
  "JNJ.VI": {
    "city": "New Brunswick",
    "country": "United States",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Johnson & Johnson",
    "market": "at_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "JOHNSON & JOHNSON",
    "state": "NJ",
    "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
    "website": "http://www.jnj.com",
    "zipcode": "08933"
  },
  "JNJB34.SA": {
    "city": "New Brunswick",
    "country": "United States",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Johnson & Johnson",
    "market": "br_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "JOHNSON     DRN",
    "state": "NJ",
    "summary": "Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.",
    "website": "http://www.jnj.com",
    "zipcode": "08933"
  },
  "KILITCH.NS": {
    "city": "Mumbai",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "Kilitch Drugs (India) Limited",
    "market": "in_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "KILITCH DRUGS(INDI",
    "state": null,
    "summary": "Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and a range of nutritional products comprising CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.",
    "website": "http://www.kilitch.com",
    "zipcode": "400088"
  },
  "KLBF.JK": {
    "city": "Jakarta",
    "country": "Indonesia",
    "currency": "IDR",
    "exchange": "JKT",
    "industry": "Drug Manufacturers - General",
    "long_name": "PT Kalbe Farma Tbk.",
    "market": "id_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Kalbe Farma Tbk.",
    "state": null,
    "summary": "PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. It operates in four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. The company offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. It also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, pre-teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, the company operates Mitrasana Clinics, a health care service; contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products. Further, it offers health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as provides advertising services. The company was incorporated in 1966 and is headquartered in Jakarta, Indonesia. PT Kalbe Farma Tbk. is a subsidiary of PT Gira Sole Prima.",
    "website": "http://www.kalbe.co.id",
    "zipcode": "10510"
  },
  "KOPRAN.NS": {
    "city": "Mumbai",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "Kopran Limited",
    "market": "in_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KOPRAN LTD",
    "state": null,
    "summary": "Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers finished dosage forms, including tablets, capsules, dry powder, suspension, and injectable in various therapeutic areas comprising cardiovascular, gastrointestinal, pain management, oncology, anti-allergic, central nervous system, erectile dysfunction, and others, as well as antibiotics, anti-diabetic, respiratory, anthelmentics, antiprotozoals, and antipeptic ulcer and gut. It also provides active pharmaceutical ingredients in the categories of anti-hypertensive, macrolide, neuromodulator, sterile cephalosporins, carbapenems, anti-acne, anti-ulcerant, anti-depressent, anti-infective, urological, and anti-thrombotic. The company was incorporated in 1958 and is headquartered in Mumbai, India.",
    "website": "http://www.kopran.com",
    "zipcode": "400018"
  },
  "KY4.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Kyowa Kirin Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "KYOWA KIRIN CO. LTD.",
    "state": null,
    "summary": "Kyowa Kirin Co., Ltd., a specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has strategic research alliance with Harvard University. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",
    "website": "http://www.kyowakirin.com",
    "zipcode": "100-0004"
  },
  "KYKOF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Kyowa Kirin Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "KYOWA KIRIN CO LTD",
    "state": null,
    "summary": "Kyowa Kirin Co., Ltd., a specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has strategic research alliance with Harvard University. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",
    "website": "http://www.kyowakirin.com",
    "zipcode": "100-0004"
  },
  "L7R.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Lipidor AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIPIDOR AB",
    "state": null,
    "summary": "Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, and AKP-03 AKP-07 for eczema. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, and acne and wart treatment. The company has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. Lipidor AB (publ) was founded in 2009 and is based in Stockholm, Sweden.",
    "website": "http://lipidor.se",
    "zipcode": "106 91"
  },
  "LILY34.SA": {
    "city": "Indianapolis",
    "country": "United States",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Eli Lilly and Company",
    "market": "br_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "LILLY       DRN",
    "state": "IN",
    "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
    "website": "http://www.lilly.com",
    "zipcode": "46285"
  },
  "LIPI.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Lipidor AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Lipidor AB",
    "state": null,
    "summary": "Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, and AKP-03 AKP-07 for eczema. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, and acne and wart treatment. The company has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. Lipidor AB (publ) was founded in 2009 and is based in Stockholm, Sweden.",
    "website": "http://lipidor.se",
    "zipcode": "106 91"
  },
  "LLY": {
    "city": "Indianapolis",
    "country": "United States",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Eli Lilly and Company",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Eli Lilly and Company",
    "state": "IN",
    "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
    "website": "http://www.lilly.com",
    "zipcode": "46285"
  },
  "LLY.DE": {
    "city": "Indianapolis",
    "country": "United States",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "Eli Lilly and Company",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ELI LILLY",
    "state": "IN",
    "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
    "website": "http://www.lilly.com",
    "zipcode": "46285"
  },
  "LLY.F": {
    "city": "Indianapolis",
    "country": "United States",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Eli Lilly and Company",
    "market": "dr_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ELI LILLY",
    "state": "IN",
    "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
    "website": "http://www.lilly.com",
    "zipcode": "46285"
  },
  "LLY.MX": {
    "city": "Indianapolis",
    "country": "United States",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Eli Lilly and Company",
    "market": "mx_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ELI LILLY AND COMPANY",
    "state": "IN",
    "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
    "website": "http://www.lilly.com",
    "zipcode": "46285"
  },
  "LLY.SW": {
    "city": "Indianapolis",
    "country": "United States",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Eli Lilly and Company",
    "market": "ch_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "LILLY ELI",
    "state": "IN",
    "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
    "website": "http://www.lilly.com",
    "zipcode": "46285"
  },
  "LLYC.VI": {
    "city": "Indianapolis",
    "country": "United States",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Eli Lilly and Company",
    "market": "at_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ELI LILLY CO",
    "state": "IN",
    "summary": "Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
    "website": "http://www.lilly.com",
    "zipcode": "46285"
  },
  "LUP.F": {
    "city": "Yantai",
    "country": "China",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Luye Pharma Group Ltd.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "LUYE PHARMA GROUP DL-,02",
    "state": null,
    "summary": "Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and treatment for metastatic carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Tiandixin, a product used as an adjuvant therapy for malignant tumors, malignant hydrothorax and ascites, and respiratory infections; and Yitaida for acute promyelocytic leukemia and liver cancer. It also provides Rykindo, an injection for the treatment of acute and chronic schizophrenia; Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for the treatment of cancer pain; and Buprenorphine Transdermal Patch for the treatment of chronic pain. In addition, it offers Beixi, an acarbose capsule for diabetes; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; Beitangning, a pioglitazone hydrochloride capsule to control blood glucose; Nuosen for acute upper digestive tract hemorrhage; and Sailimai for the treatment of diarrhea. Further, it provides Xuezhikang, a lipid adjusting capsule; Maitongna for cerebral edema and swelling by trauma; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; Fengshiye for patients who have pains in bones, joints, and limbs; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; and glucosamine hydrochloride tablets for osteoarthritis. Additionally, it distributes and sells pharmaceutical drugs; and manufactures and sells of biopharmaceutical products. The company was founded in 1994 and is headquartered in Yantai, the People's Republic of China.",
    "website": "http://www.luye.cn",
    "zipcode": "264003"
  },
  "MARKSANS.NS": {
    "city": "Mumbai",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "Marksans Pharma Limited",
    "market": "in_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MARKSANS PHARMA LT",
    "state": null,
    "summary": "Marksans Pharma Limited, together with its subsidiaries, researches, develops, manufactures, markets, distributes, and sells generic pharmaceutical formulations in North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the analgesic, anti-inflammatory, benign prostatic hyperplasia, epilepsy, hyperparathyroidism, diabetic and antidiabetic, pain management, neurology, antacid, hormonal, antifungal, antiulcerative, cardiovascular and central nervous system, vitamin, cough and cold, dermatology, gastrointestinal, gynecology, cephalosporin, injectable, antibacterial, hypertension, oncology, and antibiotics and anti-allergic therapeutic areas. It also provides contract research and manufacturing services; and develops and out-licenses patented products. The company was incorporated in 1992 and is headquartered in Mumbai, India.",
    "website": "http://www.marksanspharma.com",
    "zipcode": "400053"
  },
  "MAYNF": {
    "city": "Salisbury South",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Mayne Pharma Group Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MAYNE PHARMA GROUP LIMITED",
    "state": "SA",
    "summary": "Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. The company operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. It also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.",
    "website": "http://www.maynepharma.com",
    "zipcode": "5106"
  },
  "MRCK34.SA": {
    "city": "Kenilworth",
    "country": "United States",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Merck & Co., Inc.",
    "market": "br_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK       DRN",
    "state": "NJ",
    "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
    "website": "http://www.merck.com",
    "zipcode": "07033"
  },
  "MRK": {
    "city": "Kenilworth",
    "country": "United States",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Merck & Co., Inc.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Merck & Company, Inc.",
    "state": "NJ",
    "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
    "website": "http://www.merck.com",
    "zipcode": "07033"
  },
  "MRK.BA": {
    "city": "Kenilworth",
    "country": "United States",
    "currency": "ARS",
    "exchange": "BUE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Merck & Co., Inc.",
    "market": "ar_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK & CO INC",
    "state": "NJ",
    "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
    "website": "http://www.merck.com",
    "zipcode": "07033"
  },
  "MRK.MX": {
    "city": "Kenilworth",
    "country": "United States",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Merck & Co., Inc.",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK & CO INC",
    "state": "NJ",
    "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
    "website": "http://www.merck.com",
    "zipcode": "07033"
  },
  "MRK.PA": {
    "city": "Kenilworth",
    "country": "United States",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Drug Manufacturers - General",
    "long_name": "Merck & Co., Inc.",
    "market": "fr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK AND CO INC",
    "state": "NJ",
    "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
    "website": "http://www.merck.com",
    "zipcode": "07033"
  },
  "MRK.SN": {
    "city": "Kenilworth",
    "country": "United States",
    "currency": "USD",
    "exchange": "SGO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Merck & Co., Inc.",
    "market": "cl_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK & CO INC",
    "state": "NJ",
    "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
    "website": "http://www.merck.com",
    "zipcode": "07033"
  },
  "MRK.VI": {
    "city": "Kenilworth",
    "country": "United States",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Merck & Co., Inc.",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK & CO. INC.",
    "state": "NJ",
    "summary": "Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.",
    "website": "http://www.merck.com",
    "zipcode": "07033"
  },
  "MYX.AX": {
    "city": "Salisbury South",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Mayne Pharma Group Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "M PHARMA FPO",
    "state": "SA",
    "summary": "Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. The company operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. It also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.",
    "website": "http://www.maynepharma.com",
    "zipcode": "5106"
  },
  "N1A.F": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Navamedic ASA",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NAVAMEDIC ASA  NK 1",
    "state": null,
    "summary": "Navamedic ASA, a pharmaceutical company, markets and sells pharmaceuticals and other health care products in Northern European region. The company's product portfolio includes generic, branded, and patented pharmaceuticals, as well as medical devices, food supplements, cosmetics, and other health care products. It also distributes medical nutrition products for various metabolic disorders, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia type 1, MMA/PA, IVA, renal, MCT, low protein, single dose amino acids, glycogen storage disease, and ketogenic diet, as well as other products. In addition, the company sells consumer care products consisting of non-prescription drugs and health care products primarily through pharmacies and drugstores. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.",
    "website": "http://www.navamedic.com",
    "zipcode": "0255"
  },
  "NAVA.OL": {
    "city": "Oslo",
    "country": "Norway",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Navamedic ASA",
    "market": "no_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NAVAMEDIC ASA",
    "state": null,
    "summary": "Navamedic ASA, a pharmaceutical company, markets and sells pharmaceuticals and other health care products in Northern European region. The company's product portfolio includes generic, branded, and patented pharmaceuticals, as well as medical devices, food supplements, cosmetics, and other health care products. It also distributes medical nutrition products for various metabolic disorders, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia type 1, MMA/PA, IVA, renal, MCT, low protein, single dose amino acids, glycogen storage disease, and ketogenic diet, as well as other products. In addition, the company sells consumer care products consisting of non-prescription drugs and health care products primarily through pharmacies and drugstores. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.",
    "website": "http://www.navamedic.com",
    "zipcode": "0255"
  },
  "NEVPF": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Abliva AB (publ)",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ABLIVA AB",
    "state": null,
    "summary": "Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
    "website": "http://abliva.com",
    "zipcode": "223 81"
  },
  "NOTA.F": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS NAM. ADR 1",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NOVN.SW": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "ch_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS N",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NOVNEE.SW": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "ch_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS  N 2. LINIE",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NTP.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Abliva AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ABLIVA AB AK",
    "state": null,
    "summary": "Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
    "website": "http://abliva.com",
    "zipcode": "223 81"
  },
  "NVS": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Novartis AG",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NVS.BA": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "ARS",
    "exchange": "BUE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "ar_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS AG",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NVSEF": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS AG",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "NVSN.MX": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Novartis AG",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVARTIS AG",
    "state": null,
    "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
    "website": "http://www.novartis.com",
    "zipcode": "4056"
  },
  "OFK.F": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ORION CORP. B",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  },
  "ON4.MU": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Drug Manufacturers - General",
    "long_name": "Ono Pharmaceutical Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ONO PHARMACEUT.",
    "state": null,
    "summary": "Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.",
    "website": "http://www.ono.co.jp",
    "zipcode": "541-8564"
  },
  "OPHLY": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Ono Pharmaceutical Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ONO PHARMACEUTICAL CO",
    "state": null,
    "summary": "Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.",
    "website": "http://www.ono.co.jp",
    "zipcode": "541-8564"
  },
  "ORINF": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ORION CORPORATION",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  },
  "ORNAV.HE": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "fi_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Orion Corporation A",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  },
  "ORNBV.HE": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "fi_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Orion Corporation B",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  },
  "OS1.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Otsuka Holdings Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OTSUKA HOLDINGS CO.LTD.",
    "state": null,
    "summary": "Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of central nervous system, oncology, cardiovascular system, gastroenterology, ophthalmology, diagnostics, and I.V. solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÃ Jelly, a conditioning food product; BODYMAINTÃ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; SOYJOY, a soy bar; OS-1, an oral rehydration solution; HINE E-GEL, a concentrated liquid diet; PROCESSLEAD, a chew and swallow managing food; REHADAYS, a beverage to support exercise and rehabilitation; Oronine H Ointment, a household antiseptic medicine; and vitamin tonics, herbal digestive drinks, and herbal crude drugs. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 2008 and is headquartered in Tokyo, Japan.",
    "website": "http://www.otsuka.com/en",
    "zipcode": "101-0048"
  },
  "OTSKF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Otsuka Holdings Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OTSUKA HLDGS CO LTD",
    "state": null,
    "summary": "Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of central nervous system, oncology, cardiovascular system, gastroenterology, ophthalmology, diagnostics, and I.V. solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÃ Jelly, a conditioning food product; BODYMAINTÃ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; SOYJOY, a soy bar; OS-1, an oral rehydration solution; HINE E-GEL, a concentrated liquid diet; PROCESSLEAD, a chew and swallow managing food; REHADAYS, a beverage to support exercise and rehabilitation; Oronine H Ointment, a household antiseptic medicine; and vitamin tonics, herbal digestive drinks, and herbal crude drugs. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 2008 and is headquartered in Tokyo, Japan.",
    "website": "http://www.otsuka.com/en",
    "zipcode": "101-0048"
  },
  "OTSKY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Otsuka Holdings Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OTSUKA HLDGS CO LTD",
    "state": null,
    "summary": "Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of central nervous system, oncology, cardiovascular system, gastroenterology, ophthalmology, diagnostics, and I.V. solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÃ Jelly, a conditioning food product; BODYMAINTÃ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; SOYJOY, a soy bar; OS-1, an oral rehydration solution; HINE E-GEL, a concentrated liquid diet; PROCESSLEAD, a chew and swallow managing food; REHADAYS, a beverage to support exercise and rehabilitation; Oronine H Ointment, a household antiseptic medicine; and vitamin tonics, herbal digestive drinks, and herbal crude drugs. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 2008 and is headquartered in Tokyo, Japan.",
    "website": "http://www.otsuka.com/en",
    "zipcode": "101-0048"
  },
  "OZTA.F": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS SA INH. A  EO-,25",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "PFE": {
    "city": "New York",
    "country": "United States",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pfizer Inc.",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "Pfizer, Inc.",
    "state": "NY",
    "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
    "website": "http://www.pfizer.com",
    "zipcode": "10017"
  },
  "PFE.BA": {
    "city": "New York",
    "country": "United States",
    "currency": "ARS",
    "exchange": "BUE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pfizer Inc.",
    "market": "ar_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "PFIZER INC",
    "state": "NY",
    "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
    "website": "http://www.pfizer.com",
    "zipcode": "10017"
  },
  "PFE.DE": {
    "city": "New York",
    "country": "United States",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pfizer Inc.",
    "market": "de_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "PFIZER INC.  DL-,05",
    "state": "NY",
    "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
    "website": "http://www.pfizer.com",
    "zipcode": "10017"
  },
  "PFE.F": {
    "city": "New York",
    "country": "United States",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pfizer Inc.",
    "market": "dr_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "PFIZER INC.  DL-,05",
    "state": "NY",
    "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
    "website": "http://www.pfizer.com",
    "zipcode": "10017"
  },
  "PFE.MX": {
    "city": "New York",
    "country": "United States",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pfizer Inc.",
    "market": "mx_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "PFIZER INC",
    "state": "NY",
    "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
    "website": "http://www.pfizer.com",
    "zipcode": "10017"
  },
  "PFE.SN": {
    "city": "New York",
    "country": "United States",
    "currency": "USD",
    "exchange": "SGO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pfizer Inc.",
    "market": "cl_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "PFIZER INC",
    "state": "NY",
    "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
    "website": "http://www.pfizer.com",
    "zipcode": "10017"
  },
  "PFE.ST": {
    "city": "New York",
    "country": "United States",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pfizer Inc.",
    "market": "se_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "Pfizer Inc.",
    "state": "NY",
    "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
    "website": "http://www.pfizer.com",
    "zipcode": "10017"
  },
  "PFE.VI": {
    "city": "New York",
    "country": "United States",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pfizer Inc.",
    "market": "at_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "PFIZER INC",
    "state": "NY",
    "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
    "website": "http://www.pfizer.com",
    "zipcode": "10017"
  },
  "PFIZ34.SA": {
    "city": "New York",
    "country": "United States",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pfizer Inc.",
    "market": "br_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "PFIZER      DRN",
    "state": "NY",
    "summary": "Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.",
    "website": "http://www.pfizer.com",
    "zipcode": "10017"
  },
  "PFIZER.NS": {
    "city": "Mumbai",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pfizer Limited",
    "market": "in_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "PFIZER LTD",
    "state": null,
    "summary": "Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. It offers its various products in various therapeutic areas, including anti-allergic, anti-diabetic, antihistamine, anti-infective, anti-parasitic, cardiovascular, dermatology, erectile dysfunction, neurology, pain/fever/inflammation, pediatrics, psychiatry, respiratory, urology, women's health, central nervous system, autoimmune disorders, and gastrointestinal. The company also provides multivitamins, vitamins/minerals, antibiotics, steroids, vaccines, and consumer healthcare products. It sells its products through a network of independent distributors primarily under the Minipress XL, Folvite, Magnex, Eliquis, Gelusil, Lyrica, Ovral L, Citralka, Prevenar 13, Autrin, Zavicefta, Wysolone, Xeljanz, Corex, Mucaine, Becosules, Ativan, Neksium, Meronem, And Dolonex brand names. Pfizer Limited has a strategic partnership with GlobalSpace Technologies Limited to leverage the Makebot platform for vaccine awareness and DocExa platform for consultation by specialists. The company was incorporated in 1950 and is headquartered in Mumbai, India.",
    "website": "http://www.pfizerindia.com",
    "zipcode": "400051"
  },
  "PNVL3.SA": {
    "city": "Eldorado do Sul",
    "country": "Brazil",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Dimed S.A. Distribuidora de Medicamentos",
    "market": "br_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DIMED       ON      N2",
    "state": "RS",
    "summary": "Dimed S.A. Distribuidora de Medicamentos trades in medicines, perfumeries, personal hygiene and beauty products, cosmetics, and dermocosmetics in Brazil. It operates in Retail and Wholesale segments. The company offers products through distribution centers in the states of Rio Grande do Sul and EspÃ­rito Santo. It operates 444 stores in Rio Grande do Sul, Santa Catarina, ParanÃ¡, and SÃ£o Paulo. The company was formerly known as Panvel S.A. Drogarias e Farmacias and changed its name to Dimed S.A. Distribuidora de Medicamentos in April 2000. Dimed S.A. Distribuidora de Medicamentos is headquartered in Eldorado do Sul, Brazil.",
    "website": "http://www.dimed.com.br",
    "zipcode": null
  },
  "PNVL4.SA": {
    "city": "Eldorado do Sul",
    "country": "Brazil",
    "currency": "BRL",
    "exchange": "SAO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Dimed S.A. Distribuidora de Medicamentos",
    "market": "br_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DIMED       PN      N2",
    "state": "RS",
    "summary": "Dimed S.A. Distribuidora de Medicamentos trades in medicines, perfumeries, personal hygiene and beauty products, cosmetics, and dermocosmetics in Brazil. It operates in Retail and Wholesale segments. The company offers products through distribution centers in the states of Rio Grande do Sul and EspÃ­rito Santo. It operates 444 stores in Rio Grande do Sul, Santa Catarina, ParanÃ¡, and SÃ£o Paulo. The company was formerly known as Panvel S.A. Drogarias e Farmacias and changed its name to Dimed S.A. Distribuidora de Medicamentos in April 2000. Dimed S.A. Distribuidora de Medicamentos is headquartered in Eldorado do Sul, Brazil.",
    "website": "http://www.dimed.com.br",
    "zipcode": null
  },
  "PRL.MI": {
    "city": "Capua",
    "country": "Italy",
    "currency": "EUR",
    "exchange": "MIL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pierrel S.p.A.",
    "market": "it_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PIERREL",
    "state": "CE",
    "summary": "Pierrel S.p.A. provides contract manufacturing services to the life science, biopharma, and pharmaceutical industries worldwide. The company is involved in the development of various types of drugs, such as tube vials, bottles, ampoules, drops, sprays, syrups, gels, creams, ointments, and tablets; and production of active ingredients, including active substances and pharmaceutical formulations, as well as develops and manufactures dental anesthetics under the Orabloc brand name. It also engages in the development, registration, and licensing of new drugs and medical devices. Pierrel S.p.A. is based in Capua, Italy.",
    "website": "http://www.pierrelgroup.com",
    "zipcode": "81043"
  },
  "PSYG.CN": {
    "city": "Toronto",
    "country": "Canada",
    "currency": "CAD",
    "exchange": "CNQ",
    "industry": "Drug Manufacturers - General",
    "long_name": "Psyence Group Inc.",
    "market": "ca_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "PsyenceGroup",
    "state": "ON",
    "summary": "Psyence Group Inc. engages in the commercial psilocybin cultivation and production activities. Its natural psilocybin is used for the long-term treatment of psychological trauma and its mental health consequences. The company is based in Toronto, Canada.",
    "website": "http://www.psyence.com",
    "zipcode": "M5J 2J1"
  },
  "PTKFF": {
    "city": "Jakarta",
    "country": "Indonesia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "PT Kalbe Farma Tbk.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "KALBE FARMA",
    "state": null,
    "summary": "PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. It operates in four division: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The company offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. It also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, pre-teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, the company operates Mitrasana Clinics, a health care service; contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products. Further, it offers health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as provides advertising services. The company was founded in 1966 and is headquartered in Jakarta, Indonesia. PT Kalbe Farma Tbk. is a subsidiary of PT Gira Sole Prima.",
    "website": "http://www.kalbe.co.id",
    "zipcode": "10510"
  },
  "PTKFY": {
    "city": "Jakarta",
    "country": "Indonesia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "PT Kalbe Farma Tbk.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "KALBE FARMA",
    "state": null,
    "summary": "PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. It operates in four division: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The company offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. It also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, pre-teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, the company operates Mitrasana Clinics, a health care service; contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products. Further, it offers health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as provides advertising services. The company was founded in 1966 and is headquartered in Jakarta, Indonesia. PT Kalbe Farma Tbk. is a subsidiary of PT Gira Sole Prima.",
    "website": "http://www.kalbe.co.id",
    "zipcode": "10510"
  },
  "PXS.AX": {
    "city": "Frenchs Forest",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pharmaxis Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMAXIS FPO",
    "state": "NSW",
    "summary": "Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.",
    "website": "http://www.pharmaxis.com.au",
    "zipcode": "2086"
  },
  "PXSLY": {
    "city": "Frenchs Forest",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pharmaxis Ltd",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMAXIS",
    "state": "NSW",
    "summary": "Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.",
    "website": "http://www.pharmaxis.com.au",
    "zipcode": "2086"
  },
  "RCDTF": {
    "city": "Milan",
    "country": "Italy",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Recordati Industria Chimica e Farmaceutica S.p.A.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "RECORDATI",
    "state": "MI",
    "summary": "Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. is a subsidiary of Fimei - Finanziaria Industriale Mobiliare ed Immobiliare S.P.A.",
    "website": "http://www.recordati.com",
    "zipcode": "20148"
  },
  "REC.MI": {
    "city": "Milan",
    "country": "Italy",
    "currency": "EUR",
    "exchange": "MIL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Recordati Industria Chimica e Farmaceutica S.p.A.",
    "market": "it_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "RECORDATI ORD",
    "state": "MI",
    "summary": "Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. is a subsidiary of Fimei - Finanziaria Industriale Mobiliare ed Immobiliare S.P.A.",
    "website": "http://www.recordati.com",
    "zipcode": "20148"
  },
  "REC.VI": {
    "city": "Milan",
    "country": "Italy",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Recordati Industria Chimica e Farmaceutica S.p.A.",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "RECORDATI SPA",
    "state": "MI",
    "summary": "Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. is a subsidiary of Fimei - Finanziaria Industriale Mobiliare ed Immobiliare S.P.A.",
    "website": "http://www.recordati.com",
    "zipcode": "20148"
  },
  "RER1.F": {
    "city": "Milan",
    "country": "Italy",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Recordati Industria Chimica e Farmaceutica S.p.A.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "RECORDATI SPA  EO -,125",
    "state": "MI",
    "summary": "Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. is a subsidiary of Fimei - Finanziaria Industriale Mobiliare ed Immobiliare S.P.A.",
    "website": "http://www.recordati.com",
    "zipcode": "20148"
  },
  "RHHBF": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE HOLDINGS AG",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "RHHBY": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE HOLDINGS AG",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "RHHVF": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE HOLDINGS AG",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "RHO6.F": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "dr_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE HLDG SP.ADR 1/8",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "RO.SW": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "ch_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE I",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "ROG.SW": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "ch_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE GS",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "ROGN.MX": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Roche Holding AG",
    "market": "mx_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "ROCHE HOLDINGS AG",
    "state": null,
    "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
    "website": "http://www.roche.com",
    "zipcode": "4070"
  },
  "SAN.PA": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Drug Manufacturers - General",
    "long_name": "Sanofi",
    "market": "fr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SANOFI",
    "state": null,
    "summary": "Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
    "website": "http://www.sanofi.com",
    "zipcode": "75008"
  },
  "SANF.MI": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "MIL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Sanofi",
    "market": "it_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SANOFI",
    "state": null,
    "summary": "Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
    "website": "http://www.sanofi.com",
    "zipcode": "75008"
  },
  "SANO.VI": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Sanofi",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SANOFI SA",
    "state": null,
    "summary": "Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
    "website": "http://www.sanofi.com",
    "zipcode": "75008"
  },
  "SANOFI.NS": {
    "city": "Mumbai",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "Sanofi India Limited",
    "market": "in_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SANOFI INDIA LTD",
    "state": null,
    "summary": "Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, allergy and vitamins, and minerals and supplements. The company exports its products to approximately 50 countries, including Germany, the Czech Republic, Australia, the United Kingdom, and Russia. It sells its products under the Lantus, Toujeo, Amaryl, Clexane, Cardace, Targocid, Valparin, Allegra, Avil, Combiflam, and DePura by Sanofi brands through independent distributors. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.",
    "website": "http://www.sanofiindialtd.com",
    "zipcode": "400072"
  },
  "SHEZF": {
    "city": "Shenzhen",
    "country": "China",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SHENZHEN HEPALINK PHARMACEUTICA",
    "state": null,
    "summary": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through three segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), and CDMO. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, including pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; and trading of medical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.",
    "website": "http://www.hepalink.com",
    "zipcode": "518057"
  },
  "SMSPHARMA.NS": {
    "city": "Hyderabad",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "SMS Pharmaceuticals Limited",
    "market": "in_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SMS PHARMACEUTICAL",
    "state": null,
    "summary": "SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, antipsychotic, anti-hypertensive, anti-anginal, anti-viral, urinary antispasmodic, and anti-retroviral APIs. It is also involved in the contract research activities. In addition, the company exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India.",
    "website": "http://www.smspharma.com",
    "zipcode": "500034"
  },
  "SNPHY": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Santen Pharmaceutical Co., Ltd.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SANTEN PHARMACEUTICAL CO",
    "state": null,
    "summary": "Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase 2b clinical trial; DE-128 in Europe, as well as is in Phase 2/3 clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase 3 clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase 2/3 clinical trial in Japan, as well as is in Phase 3 in Asia; and MD-16 for the treatment of cataract. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.",
    "website": "http://www.santen.com",
    "zipcode": "530-8552"
  },
  "SNW.DE": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "Sanofi",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SANOFI SA INHABER  EO 2",
    "state": null,
    "summary": "Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
    "website": "http://www.sanofi.com",
    "zipcode": "75008"
  },
  "SNW.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Sanofi",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SANOFI SA INHABER  EO 2",
    "state": null,
    "summary": "Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
    "website": "http://www.sanofi.com",
    "zipcode": "75008"
  },
  "SNW2.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Sanofi",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SANOFI SA ADR 1/2/EO 2",
    "state": null,
    "summary": "Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
    "website": "http://www.sanofi.com",
    "zipcode": "75008"
  },
  "SNY": {
    "city": "Paris",
    "country": "France",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Sanofi",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Sanofi",
    "state": null,
    "summary": "Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
    "website": "http://www.sanofi.com",
    "zipcode": "75008"
  },
  "SNYNF": {
    "city": "Paris",
    "country": "France",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Sanofi",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SANOFI",
    "state": null,
    "summary": "Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
    "website": "http://www.sanofi.com",
    "zipcode": "75008"
  },
  "SZD.F": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Santen Pharmaceutical Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SANTEN PHARMA.",
    "state": null,
    "summary": "Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase 2b clinical trial; DE-128 in Europe, as well as is in Phase 2/3 clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase 3 clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase 2/3 clinical trial in Japan, as well as is in Phase 3 in Asia; and MD-16 for the treatment of cataract. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.",
    "website": "http://www.santen.com",
    "zipcode": "530-8552"
  },
  "TGRNF": {
    "city": "Beijing",
    "country": "China",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Tong Ren Tang Technologies Co. Ltd.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TONG REN TANG TECHNOLOGIES CO",
    "state": null,
    "summary": "Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicines in Mainland China, Hong Kong, and internationally. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, foot care products, and healthcare products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in the technological development and sale of biological products, Chinese and Western medicines, and cosmetics; wholesale and retail sale of Chinese medicines and healthcare products; and internal and external surgery, medical examination, and hospital management activities. Further, it produces and processes biochemical products; extracts and processes plants; and produces food products. The company was founded in 1669 and is based in Beijing, the People's Republic of China.",
    "website": "http://www.tongrentangkj.com",
    "zipcode": "100079"
  },
  "TNG.F": {
    "city": "Beijing",
    "country": "China",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Tong Ren Tang Technologies Co. Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TONG REN TANG TECHS NEW H",
    "state": null,
    "summary": "Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicines in Mainland China, Hong Kong, and internationally. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, foot care products, and healthcare products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in the technological development and sale of biological products, Chinese and Western medicines, and cosmetics; wholesale and retail sale of Chinese medicines and healthcare products; and internal and external surgery, medical examination, and hospital management activities. Further, it produces and processes biochemical products; extracts and processes plants; and produces food products. The company was founded in 1669 and is based in Beijing, the People's Republic of China.",
    "website": "http://www.tongrentangkj.com",
    "zipcode": "100079"
  },
  "TORNTPHARM.NS": {
    "city": "Ahmedabad",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "Torrent Pharmaceuticals Limited",
    "market": "in_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "TORRENT PHARM",
    "state": null,
    "summary": "Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, anti-infective, vitamin minerals nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.",
    "website": "http://www.torrentpharma.com",
    "zipcode": "380009"
  },
  "TTKHLTCARE.NS": {
    "city": "Chennai",
    "country": "India",
    "currency": "INR",
    "exchange": "NSI",
    "industry": "Drug Manufacturers - General",
    "long_name": "TTK Healthcare Limited",
    "market": "in_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "TTK HEALTHCARE",
    "state": null,
    "summary": "TTK Healthcare Limited engages in the pharmaceutical, consumer product, medical device, protective device, and food businesses in India and internationally. The company's Pharmaceuticals segment deals in herbal and allopathic formulations in various therapeutic areas for human and veterinary uses. It also provides delivery care, female healthcare, haematinic, pain management, neurotrophic, gastro intestinal, male and female fertility, nutritional, cardiac care, derma, urinary specialties, and respiratory care products, as well as calcium supplements. Its Consumer Products segment is involved in marketing and distribution of Woodwards's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, air fresheners, etc. The company's Medical Devices segment manufactures and distributes artificial heart valves; and develops orthopedic implants and instruments. Its Protective Devices segment manufactures and markets male contraceptives and other allied products. The company's Foods segment manufactures and markets food products, including potato and cereal based pellets. Its Others segment prints and publishes maps and atlases. The company was incorporated in 1958 and is headquartered in Chennai, India. TTK Healthcare Limited is a subsidiary of T T Krishnamachari & Co., Ltd.",
    "website": "http://www.ttkhealthcare.com",
    "zipcode": "600086"
  },
  "UNJ.F": {
    "city": "Yuen Long",
    "country": "Hong Kong",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "The United Laboratories International Holdings Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "UNITED LABS INTL  HD -,01",
    "state": null,
    "summary": "The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Intermediate Products, Bulk Medicine, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings and organic fertilizers; holds trademarks; trades in pharmaceutical products; and engages in the food production activities. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.",
    "website": "http://www.tul.com.cn",
    "zipcode": null
  },
  "UUD.F": {
    "city": "Frenchs Forest",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pharmaxis Ltd",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMAXIS LTD.",
    "state": "NSW",
    "summary": "Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.",
    "website": "http://www.pharmaxis.com.au",
    "zipcode": "2086"
  },
  "V16.F": {
    "city": "Carros",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Virbac SA",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "VIRBAC SA  EO 1,25",
    "state": null,
    "summary": "Virbac SA manufactures and sells pharmaceutical, biological, nutritional, and diagnostic products for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, and the Middle East and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. Virbac SA was founded in 1968 and is headquartered in Carros, France.",
    "website": "http://corporate.virbac.com",
    "zipcode": "06511"
  },
  "V4TA.F": {
    "city": "Chippenham",
    "country": "United Kingdom",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Vectura Group plc",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "VECTURA GROUP LS -,000271",
    "state": null,
    "summary": "Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.",
    "website": "http://www.vectura.com",
    "zipcode": "SN14 6FH"
  },
  "VEC.L": {
    "city": "Chippenham",
    "country": "United Kingdom",
    "currency": "GBp",
    "exchange": "LSE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Vectura Group plc",
    "market": "gb_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "VECTURA GROUP PLC ORD 0.0271P",
    "state": null,
    "summary": "Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.",
    "website": "http://www.vectura.com",
    "zipcode": "SN14 6FH"
  },
  "VEGPF": {
    "city": "Chippenham",
    "country": "United Kingdom",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Vectura Group plc",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "VECTURA GROUP",
    "state": null,
    "summary": "Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.",
    "website": "http://www.vectura.com",
    "zipcode": "SN14 6FH"
  },
  "VIRP.PA": {
    "city": "Carros",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Drug Manufacturers - General",
    "long_name": "Virbac SA",
    "market": "fr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "VIRBAC",
    "state": null,
    "summary": "Virbac SA manufactures and sells pharmaceutical, biological, nutritional, and diagnostic products for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, and the Middle East and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. Virbac SA was founded in 1968 and is headquartered in Carros, France.",
    "website": "http://corporate.virbac.com",
    "zipcode": "06511"
  },
  "YPH.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Astellas Pharma Inc.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTELLAS PHARMA INC.",
    "state": null,
    "summary": "Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.",
    "website": "http://www.astellas.com",
    "zipcode": "103-8411"
  },
  "YPHA.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Astellas Pharma Inc.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTELLAS PHARMA UNSP.ADR",
    "state": null,
    "summary": "Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.",
    "website": "http://www.astellas.com",
    "zipcode": "103-8411"
  },
  "ZEG.DE": {
    "city": "Cambridge",
    "country": "United Kingdom",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - General",
    "long_name": "AstraZeneca PLC",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTRAZENECA PLC  DL-,25",
    "state": null,
    "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
    "website": "http://www.astrazeneca.com",
    "zipcode": "CB2 0AA"
  },
  "ZEG.F": {
    "city": "Cambridge",
    "country": "United Kingdom",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "AstraZeneca PLC",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTRAZENECA PLC  DL-,25",
    "state": null,
    "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
    "website": "http://www.astrazeneca.com",
    "zipcode": "CB2 0AA"
  },
  "ZEGA.F": {
    "city": "Cambridge",
    "country": "United Kingdom",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "AstraZeneca PLC",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTRAZENECA DL-,25 SP.ADR",
    "state": null,
    "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
    "website": "http://www.astrazeneca.com",
    "zipcode": "CB2 0AA"
  }
}
